Business Context and Reporting Period
This Form 8-K is a current report filed by MEI Pharma, Inc. (not Lite Strategy, Inc.) on August 5, 2025. The filing addresses corporate governance changes under Item 5.02, specifically the departure of a director and the election of a new director.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Director Resignation: Steven D. Wood resigned as a director effective immediately on August 5, 2025. The resignation was not due to any disagreement with the Company's operations, policies, or practices.
- Director Election: Joshua Riezman was elected to the Board on August 5, 2025. He serves as Managing Director and Head of U.S. Legal and Compliance for GSR Strategies, LLC.
- Related Party Context: GSR Strategies, LLC is the Asset Manager under an Asset Management Agreement dated July 22, 2025, between GSR and the Company.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future performance. No specific risks or contingencies are disclosed in this document other than the standard disclosure that Mr. Riezman's selection was not based on any undisclosed arrangement, aside from the referenced Asset Management Agreement.
Investor Verification Checklist
- Verify the terms of the Asset Management Agreement between MEI Pharma, Inc. and GSR Strategies, LLC (filed as Exhibit 10.4 to the July 22, 2025, Form 8-K).
- Confirm the current composition of the Board of Directors following Mr. Wood's resignation and Mr. Riezman's election.
- Review the Company's recent financial filings (e.g., 10-K or 10-Q) for actual financial metrics, as this 8-K does not contain them.